Last week, BeiGene and Bio-Thera Solutions announced that the companies had entered into a license, distribution, and supply agreement for BAT1706, Biothera’s Avastin® (bevacizumab) biosimilar, in China.  According to the announcement, Bio-Thera has agreed to grant BeiGene the right to develop, manufacture, and commercialize BAT1706 in China, Hong Kong, Macau, and Taiwan for an upfront payment.  Bio-Thera is also eligible for milestone payments up to a total of $165 million.  Bio-Thera will retain its rights outside of the agreed upon territories and plans to file for marketing approval of BAT1706 in the United States and European Union in the fourth quarter of 2020.